Gut bacteria boosts cancer immunotherapy in new trial
NCT ID NCT06865521
First seen Apr 23, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This early-phase study tests whether adding Akkermansia probiotics to standard immunotherapy (anti-PD-1) is safe and possible for people with advanced colorectal cancer that hasn't responded to other treatments. About 22 adults aged 18-75 will receive the combination to monitor side effects and see if it helps shrink tumors. The goal is to improve the body's immune response against cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Colorectal Cancer, West China Hospital
Chengdu, Sichuan, 610041, China
-
Colorectal Cancer, West China Hospital
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.